NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept ...

Corcept Therapeutics' revenue from Korlym grew 40% in 2024, with 2025 guidance projecting $900-$950M, despite ongoing legal risks from Teva's generic version. The lawsuit with Teva poses a ...

O n Friday, H.C. Wainwright reiterated its Buy rating and $80.00 price target for Corcept Therapeutics (NASDAQ:CORT), highlighting the company's consistent growth in Korlym sales over the past ...

Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes Corcept Therapeutics reports positive Phase 4 CATALYST results ...

The company’s sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome or endogenous hypercortisolism, has been performing well. The drug has been witnessing ...

"Once again, we had a record number of new Korlym ® prescribers and a record number of patients receiving Korlym in the quarter. Physicians are increasingly aware of hypercortisolism’s true ...